X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims for Abbvie to focus on the CD19-directed in-situ generated CAR-T cell therapy candidates, which include UB-VV111 for the treatment of hematologic malignancies.
Lead Product(s): UB-VV111
Therapeutic Area: Oncology Product Name: UB-VV111
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $1,440.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 04, 2024
Details:
Under the collaborations, IASO Bio will receive exclusive access to the rapamycin-activated cytokine receptor platform, Umoja's synthetic cytokine receptor technology, for the development of two ex vivo iPSC-derived chimeric antigen receptor-bearing cell therapies.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: IASO Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 03, 2024
Details:
Under the collaboration, Umoja will leverage Ozette Endpoints™ and Ozette Discovery™ to enable both companies' multidisciplinary scientific and bioinformatic teams to collaborate and expand the benefits of CAR T-cell immunotherapy to patients in need.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Ozette Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 21, 2023
Details:
The collaboration will focus on bringing off-the-shelf therapies to patients with hematological malignancies, initially acute myeloid leukemia (AML), with a goal of increasing patient accessibility.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: IASO Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 21, 2022
Details:
The presentations will highlight Umoja’s complementary cell therapy platforms for in vivo CAR T-cell therapeutics and RACR-induced cytotoxic lymphocytes (iCIL).
Lead Product(s): UB-VV200
Therapeutic Area: Oncology Product Name: UB-VV200
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
New data demonstrates Umoja’s synthetic receptor enabled differentiation (ShRED™), UB-VV100 as a novel platform to differentiate and expand progenitor cells and cytotoxic innate lymphocytes using the RACRTM synthetic cytokine receptor system.
Lead Product(s): UB-VV100
Therapeutic Area: Oncology Product Name: UB-VV100
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
Preclinical safety studies completed to-date demonstrate the overall low risk for off target transduction after in vivo administration of UB-VV100 in two animal models, including a model of intranodal delivery.
Lead Product(s): UB-VV100
Therapeutic Area: Oncology Product Name: UB-VV100
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2022
Details:
Under the terms of agreement, both parties will collaborate to evaluate VivoVec delivery using the Side CAR-T™ system. Lupagen will not develop or commercialize the Side CAR-T™ device for the delivery of viral vectors in the field of oncology during the term of the agreement.
Lead Product(s): UB-VV100
Therapeutic Area: Oncology Product Name: UB-VV100
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Lupagen
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 23, 2022
Details:
UB-VV100, RACR-induced cytotoxic innate lymphocytes permit the expansion and differentiation of iPSCs with fewer limitations, leading to a more cost-effective manufacturing process.
Lead Product(s): UB-VV100
Therapeutic Area: Oncology Product Name: UB-VV100
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 04, 2022
Details:
The Seattle Children’s activation of Phase 1 ENLIGHTen clinical trial in patients with osteosarcoma to assess the safety and tolerability of autologous “universal” CAR T cells when administered with UB-TT170, the Company’s proprietary small molecule fluorescein tag.
Lead Product(s): UB-TT170,CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: UB-TT170
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
